The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 120.40
Bid: 120.00
Ask: 120.40
Change: 0.00 (0.00%)
Spread: 0.40 (0.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 120.40
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Syncona confident after Q1 market volatility

Tue, 16th Aug 2022 10:06

(Sharecast News) - Healthcare investor Syncona reported net assets of £1.33bn at the end of its first quarter on Tuesday, or 197.9p per share, up from £1.31bn and 194.4p per share at the end of March.

The FTSE 250 company said that made for a net asset value return of 1.8% in the three months ended 30 June, driven by the positive impact of foreign exchange across the portfolio and capital pool.

Its life science portfolio was valued at £561.8m, up from £524.9m, with a return of -0.2% in the quarter.

The share prices of Syncona's listed holdings were still being negatively impacted by market volatility, although the board said it remained "confident" in the fundamentals of its companies.

It added that the portfolio remained funded to deliver on upcoming clinical milestones in the 2023 financial year, with £38m deployed in the period and a capital base of £768.7m as at 30 June, down from £784.9m at the end of March.

The company said that capital base provided it with a strategic advantage, as it looked to fund "exciting" new opportunities while supporting its current portfolio.

"We are pleased with the continued progress across the Syncona portfolio during the quarter, with our companies delivering on a number of operational and clinical milestones," said Martin Murphy, chair and chief executive officer at Syncona Investment Management.

"Our strategic capital base remains a key competitive advantage, enabling us to continue to fund our companies through the current market conditions, with £38m of capital deployed in the quarter, and strongly positioning us to take advantage of exciting opportunities to found new Syncona companies."

Murphy said Syncona was founded with a long-term vision and approach to leverage its experience in managing life science companies through all market cycles.

"We are confident that we can navigate the current environment to deliver strong risk-adjusted returns for our shareholders and fulfil our purpose to extend and enhance human life."

At 0940 BST, shares in Syncona were down 0.2% at 199.2p.

Reporting by Josh White at Sharecast.com.

More News
14 Dec 2021 12:24

Syncona portfolio firm Freeline cuts workforce and narrows focus

Syncona portfolio firm Freeline cuts workforce and narrows focus

Read more
29 Nov 2021 10:04

Syncona invests GBP19 million in Quell Therapeutics via funding round

Syncona invests GBP19 million in Quell Therapeutics via funding round

Read more
22 Nov 2021 15:57

EXECUTIVE CHANGES: All change at Aura Energy amid ASX spin-out plan

EXECUTIVE CHANGES: All change at Aura Energy amid ASX spin-out plan

Read more
11 Nov 2021 14:30

IN BRIEF: Syncona net assets drop as Life Science portfolio takes hit

IN BRIEF: Syncona net assets drop as Life Science portfolio takes hit

Read more
11 Nov 2021 09:42

Syncona net asset value slips in first half

(Sharecast News) - Healthcare investor Syncona reported net assets of £1.15bn at the end of its first half on Thursday, or 171.7p per share, down from £1.3bn or 193.8p per share at the end of March.

Read more
10 Nov 2021 10:51

Syncona's Freeline loss widens but progresses on Fabry's disease drug

Syncona's Freeline loss widens but progresses on Fabry's disease drug

Read more
10 Nov 2021 08:13

Syncona's Freeline makes progress in dose-finding trials

(Sharecast News) - Healthcare company Syncona announced new data from its portfolio company Freeline Therapeutics' ongoing phase 1 and 2 'MARVEL-1' dose-finding clinical trial of 'FLT190' for the treatment of Fabry disease on Wednesday, with the second patient dosed generating "encouraging" data.

Read more
9 Nov 2021 19:18

TRADING UPDATES: Sealand's China progress; Altus finds gold

TRADING UPDATES: Sealand's China progress; Altus finds gold

Read more
8 Nov 2021 09:37

Syncona's Autolus gets USD250 million investment from Blackstone

Syncona's Autolus gets USD250 million investment from Blackstone

Read more
4 Nov 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
3 Nov 2021 14:38

TRADING UPDATES: BATM signs new deal; Synectics wins two projects

TRADING UPDATES: BATM signs new deal; Synectics wins two projects

Read more
17 Aug 2021 11:33

Syncona focuses on portfolio as net asset value drops in first quarter

Syncona focuses on portfolio as net asset value drops in first quarter

Read more
16 Aug 2021 17:57

Syncona investee Freeline CEO Heggie leaves, COO Parini replaces

Syncona investee Freeline CEO Heggie leaves, COO Parini replaces

Read more
27 Jul 2021 16:03

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
24 Jun 2021 10:20

Syncona investee Anaveon doses first patient in ANV419 trial

Syncona investee Anaveon doses first patient in ANV419 trial

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.